MET and acute myeloid leukemia: In tumor xenograft models, although a dose of 12 mg/kg LY2801653 has been shown to repress growth and progression in acute myeloid leukemia, gastric cancer, glioblastoma, pancreatic cancer, NSCLC, and colon cancer cells,48, 51, 66, 67 we found that a significant tumor growth delay was observed in high MET and AXL expression MKN45 gastric cancer model at a dose of only 3 mg/kg.